Risankizumab Eases Moderate to Severe Crohn's Disease

(MedPage Today) -- Risankizumab (Skyrizi) was safe and effective for patients with moderate to severe Crohn's disease (CD), according to two phase III induction trials and a maintenance trial.
All co-primary endpoints were met at week 12 for the...